collection
MENU ▼
Read by QxMD icon Read
search

Head and Neck cancer

shared collection
739 papers 100 to 500 followers
By Massimo Ghiani Medical Doctor involved in Head and neck cancer
https://www.readbyqxmd.com/read/24659647/clinical-benefit-of-cetuximab-and-prognostic-value-of-cetuximab-related-skin-toxicity-in-metastatic-colorectal-cancer-a-single-institution-analysis
#1
Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic, Milos Kostic, Ivan Petkovic
PURPOSE: To evaluate the clinical benefits of cetuximab (CTX) and the prognostic value of CTX-related skin toxicity in metastatic colorectal cancer (mCRC) patients. METHODS: Sixty patients were tested for KRAS mutation at the Department of Oncology, Clinical Centre Nis. We assessed 34 wild-type KRAS mCRC patients treated with CTX. All of them were refractory to prior fluoropyrimidine, oxaliplatin and irinotecan-based regimens. The maximum grade skin toxicity according to treatment cycle was analyzed...
January 2014: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/24859798/early-skin-toxicity-predicts-better-outcomes-and-early-tumor-shrinkage-predicts-better-response-after-cetuximab-treatment-in-advanced-colorectal-cancer
#2
T Kogawa, A Doi, M Shimokawa, T M Fouad, T Osuga, F Tamura, T Mizushima, T Kimura, S Abe, H Ihara, T Kukitsu, T Sumiyoshi, N Yoshizaki, M Hirayama, T Sasaki, Y Kawarada, S Kitashiro, S Okushiba, H Kondo, Y Tsuji
Cetuximab-containing treatments for metastatic colorectal cancer have been shown to have higher overall response rates and longer progression-free and overall survival than other systemic therapies. Cetuximab-related manifestations, including severe skin toxicity and early tumor shrinkage, have been shown to be predictors of response to cetuximab. We hypothesized that early skin toxicity is a predictor of response and better outcomes in patients with advanced colorectal carcinoma. We retrospectively evaluated 62 patients with colorectal adenocarcinoma who had unresectable tumors and were treated with cetuximab in our institution...
March 2015: Targeted Oncology
https://www.readbyqxmd.com/read/26469836/anti-epidermal-growth-factor-receptor-skin-toxicity-a-matter-of-topical-hydration
#3
Daris Ferrari, Carla Codecà, Barbara Bocci, Francesca Crepaldi, Martina Violati, Giulia Viale, Carmela Careri, Sarah Caldiera, Veronica Bordin, Andrea Luciani, Sabrina Zonato, Gabriela Cassinelli, Paolo Foa
Skin toxicity is a frequent complication of anti-epidermal growth factor receptor therapy, which can be an obstacle in maintaining the dose intensity and may negatively impact on the clinical outcome of cancer patients. Skin lesions depend on the disruption of the keratinocyte development pathways and no treatment is clearly effective in resolving the cutaneous alterations frequently found during anti-epidermal growth factor receptor therapy. Among systemic treatments, oral tetracycline proved to be useful in preventing skin manifestations...
February 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26811634/biomarkers-of-skin-toxicity-induced-by-anti-epidermal-growth-factor-receptor-antibody-treatment-in-colorectal-cancer
#4
REVIEW
Akiko Kubo, Hironobu Hashimoto, Naoki Takahashi, Yasuhide Yamada
Skin toxicity is a common symptom of anti-epidermal growth factor receptor (EGFR) antibody treatment and is also a predictive marker of its efficacy in colorectal cancer patients. However, severe skin disorders induced by such antibodies negatively impact on the quality of life of patients and decreases drug compliance during treatment. If we can predict the high-risk group susceptible to severe skin toxicity before treatment, we can undertake the early management of any arising skin disorders and formulate a more accurate prognosis for anti-EGFR antibody treatment...
January 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28101834/management-of-acute-skin-toxicity-with-hypericum-perforatum-and-neem-oil-during-platinum-based-concurrent-chemo-radiation-in-head-and-neck-cancer-patients
#5
Pierfrancesco Franco, Monica Rampino, Oliviero Ostellino, Marina Schena, Giancarlo Pecorari, Paolo Garzino Demo, Massimo Fasolis, Francesca Arcadipane, Stefania Martini, Chiara Cavallin, Mario Airoldi, Umberto Ricardi
Acute skin toxicity is a frequent finding during combined radiotherapy and chemotherapy in head and neck cancer patients. Its timely and appropriate management is crucial for both oncological results and patient's global quality of life. We herein report clinical data on the use of Hypericum perforatum and neem oil in the treatment of acute skin toxicity during concurrent chemo-radiation for head and neck cancer. A consecutive series of 50 head and neck cancer patients undergoing concomitant radio-chemotherapy with weekly cisplatin was analyzed...
February 2017: Medical Oncology
https://www.readbyqxmd.com/read/28104022/-immune-checkpoint-inhibitor-therapy-in-advanced-head-and-neck-cancer
#6
W Hang, Z X Xu, Q Zhang, X Lu, G Liu
Immune checkpoint inhibitor therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, improves the life quality of cancer patients and has joined the ranks of surgery, radiation, and chemotherapy to become a major choice for cancer therapy. Over the past few years, multiple exciting results have been obtained on checkpoint inhibitor therapy in advanced head and neck cancer. However, questions such as patient selection and biomarkers for assessing the therapy are largely unsolved...
January 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/28105346/human-papillomavirus-is-a-favourable-prognostic-factor-in-cancer-of-unknown-primary-in-the-head-and-neck-region-and-in-hypopharyngeal-cancer
#7
Lars Sivars, Cinzia Bersani, Nathalie Grün, Torbjörn Ramqvist, Eva Munck-Wikland, Christian Von Buchwald, Tina Dalianis
Human papillomavirus (HPV), in addition to smoking and alcohol, is a cause of oropharyngeal squamous cell carcinoma (OPSCC), particularly of the tonsils and base of the tongue (TSCC and BOTSCC, respectively). Moreover, HPV-positive TSCC and BOTSCC are associated with a better outcome compared with their HPV-negative counterparts (80 vs. 40% 3-year disease-free survival rate, respectively) and their incidence has increased in several countries. Recently, accumulating evidence of HPV in a considerable proportion of cancers of unknown primary (CUP) in the head and neck region and in a small proportion of hypopharyngeal SCCs has been reported...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28109467/dexamethasone-in-head-and-neck-cancer-patients-with-microvascular-reconstruction-no-benefit-more-complications
#8
S Kainulainen, J Törnwall, A M Koivusalo, A L Suominen, P Lassus
OBJECTIVES: Glucocorticoids are widely used in association with major surgery of the head and neck to improve postoperative rehabilitation, shorten intensive care unit and hospital stay, and reduce neck swelling. This study aimed to clarify whether peri- and postoperative use of dexamethasone in reconstructive head and neck cancer surgery is associated with any advantages or disadvantages. MATERIALS AND METHODS: This prospective double-blind randomized controlled trial comprised 93 patients...
February 2017: Oral Oncology
https://www.readbyqxmd.com/read/28109468/preclinical-models-in-hnscc-a-comprehensive-review
#9
REVIEW
Benoite Méry, Chloé Rancoule, Jean-Baptiste Guy, Sophie Espenel, Anne-Sophie Wozny, Priscilla Battiston-Montagne, Dominique Ardail, Michael Beuve, Gersende Alphonse, Claire Rodriguez-Lafrasse, Nicolas Magné
Head and neck cancer remains a significant public health concern. About 60% of patients die within 5years due to local recurrence. Head and neck squamous cell carcinoma (HNSCC) cell lines are important preclinical models in the search for new therapies against this disease. Furthermore, there is a need to test novel drugs before introduction into clinical practice. A preclinical model that closely resembles the in vivo situation would be highly valuable. In the last few decades, a multicellular spheroid model has gained attention as its behavior was comparable to in vivo tumors...
February 2017: Oral Oncology
https://www.readbyqxmd.com/read/28109473/competing-causes-of-death-in-the-head-and-neck-cancer-population
#10
Sean T Massa, Nosayaba Osazuwa-Peters, Kara M Christopher, Lauren D Arnold, Mario Schootman, Ronald J Walker, Mark A Varvares
PURPOSE/OBJECTIVES: The increasing survivorship of head and neck squamous cell carcinoma (HNSCC) comes with a risk of death from other causes, known as competing causes. The demographics of HNSCC are also evolving with increasing incidence of Human Papillomavirus (HPV) associated tumors. This study describes competing causes of death for the HNSCC population compared to the general population and identifies associated risk factors. METHODS: Adult patients with first mucosal HNSCC (2004-2011) were identified from the Surveillance, Epidemiology and End Result database...
February 2017: Oral Oncology
https://www.readbyqxmd.com/read/28108990/geographic-heterogeneity-in-the-prevalence-of-human-papillomavirus-in-head-and-neck-cancer
#11
Devasena Anantharaman, Behnoush Abedi-Ardekani, Daniel C Beachler, Tarik Gheit, Andrew F Olshan, Kathy Wisniewski, Victor Wunsch-Filho, Tatiana N Toporcov, Eloiza H Tajara, José Eduardo Levi, Raquel A Moyses, Stefania Boccia, Gabriella Cadoni, Guido Rindi, Wolfgang Ahrens, Franco Merletti, David I Conway, Sylvia Wright, Christine Carreira, Helene Renard, Priscilia Chopard, Sandrine McKay-Chopin, Ghislaine Scelo, Massimo Tommasino, Paul Brennan, Gypsyamber D'Souza
Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16(INK4a) expression to evaluate regional heterogeneity in the proportion of HPV16-associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16-positive OPSCC...
January 20, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28116983/complications-associated-with-mortality-after-head-and-neck-surgery
#12
Carolyn L Mulvey, Jason A Brant, Andrés M Bur, Jinbo Chen, John P Fischer, Steven B Cannady, Jason G Newman
Objective To determine which complications, as defined by the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database, correlate with 30-day mortality in surgery for malignancies of the head and neck. Study Design Retrospective review of prospectively collected national database. Setting NSQIP. Subjects and Methods NSQIP data from 2005 to 2014 were queried for ICD-9 codes head and neck malignancies. Multivariate logistic regression was used to examine the correlation of individual complications with 30-day mortality...
January 1, 2017: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/27881143/weekly-versus-every-three-weeks-platinum-based-chemoradiation-regimens-for-head-and-neck-cancer
#13
James M Melotek, Benjamin T Cooper, Matthew Koshy, Joshua S Silverman, Michael T Spiotto
BACKGROUND: The majority of chemoradiation (CRT) trials for locally advanced head and neck squamous cell carcinoma (HNSCC) have relied on platinum-based chemotherapy regimens administered every-3-weeks. However, given the increased utilization of weekly platinum regimens, it remains unclear how different chemotherapy schedules compare regarding efficacy and toxicity. METHODS: We retrospectively identified 212 patients with HNSCC who were treated at a single academic medical center with concurrent platinum-based CRT given weekly (N = 68) or every-three-weeks (N = 144)...
November 24, 2016: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27882552/trends-and-the-utilization-of-transoral-robotic-surgery-with-neck-dissection-in-new-york-state
#14
Catherine H Frenkel, Jie Yang, Mengru Zhang, Elliot Regenbogen, Dana A Telem, Ghassan J Samara
OBJECTIVES: The timing of neck dissection (ND) in relation to transoral robotic surgery (TORS) is controversial. This study identifies local practice patterns and economic and social access disparities during adoption of TORS. STUDY DESIGN: We analyzed utilization patterns of TORS and ND using the New York Statewide Planning and Research Cooperative System all-payer administrative database. Statewide head and neck cancer incidence from the Centers for Disease Control and Prevention (Bethesda, MD) was used to control for overall cancer incidence...
November 24, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27863190/human-papillomavirus-drives-tumor-development-throughout-the-head-and-neck-improved-prognosis-is-associated-with-an-immune-response-largely-restricted-to-the-oropharynx
#15
Ankur Chakravarthy, Stephen Henderson, Stephen M Thirdborough, Christian H Ottensmeier, Xiaoping Su, Matt Lechner, Andrew Feber, Gareth J Thomas, Tim R Fenton
Purpose In squamous cell carcinomas of the head and neck (HNSCC), the increasing incidence of oropharyngeal squamous cell carcinomas (OPSCCs) is attributable to human papillomavirus (HPV) infection. Despite commonly presenting at late stage, HPV-driven OPSCCs are associated with improved prognosis compared with HPV-negative disease. HPV DNA is also detectable in nonoropharyngeal (non-OPSCC), but its pathogenic role and clinical significance are unclear. The objectives of this study were to determine whether HPV plays a causal role in non-OPSCC and to investigate whether HPV confers a survival benefit in these tumors...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27724969/survival-outcomes-in-patients-with-oropharyngeal-cancer-treated-with-carboplatin-paclitaxel-and-concurrent-radiotherapy
#16
M Roskies, E Kay-Rivest, M A Mascarella, K Sultanem, A Mlynarek, M Hier
BACKGROUND: A commonly employed treatment for advanced staged oropharyngeal squamous cell carcinoma (OPSCC) is concurrent radiation and chemotherapy with cisplatin as the gold standard. Carboplatin is reported to have the same radiopotentiation properties and a superior side effect profile; however, its use in head and neck cancer has been limited due to the paucity of data and reported hematologic side effects. In this study, we describe our institution's experience with carboplatin, paclitaxel and radiation in the treatment of oropharyngeal squamous cell carcinoma over a 10 year period...
October 10, 2016: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27725902/hnscc-cells-resistant-to-egfr-pathway-inhibitors-are-hypermutated-and-sensitive-to-dna-damaging-substances
#17
Dominik Schulz, Markus Wirth, Guido Piontek, Anna Maria Stefanie Buchberger, Jürgen Schlegel, Rudolf Reiter, Gabriele Multhoff, Anja Pickhard
Despite remarkable successes with targeted therapies in the treatment of cancer, resistance can occur which limits the clinical outcome. In this study, we generated and characterized resistant cell clones derived from two different head and neck squamous cell carcinoma (HNSCC) cell lines (Cal27, UD-SCC-5) by long-term exposure to five targeted- and chemotherapeutics (afatinib, MK2206, BEZ235, olaparib and cisplatin). The resistant tumor cell clones showed an increased ERK1/2 expression and an altered expression of the stem-cell markers CD44, ALDH1, Oct4, Sox2, Nanog and Bmi1...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27726226/symptoms-of-patients-with-head-and-neck-cancers-undergoing-radiotherapy
#18
K Kırca, S Kutlutürkan
Radiotherapy is a reliable and effective treatment method for the treatment of head and neck cancers. This study was conducted as a descriptive work with the purpose of determining the symptoms experienced by patients with head and neck cancer who are undergoing radiotherapy. The study was carried out on 47 patients receiving treatment in oncology clinics. Data were obtained at mid-radiotherapy (RT), at the end of radiotherapy and 1 month after the end of radiotherapy using the Memorial Symptom Assessment Scale (MSAS) and Personal Information Forms...
October 10, 2016: European Journal of Cancer Care
https://www.readbyqxmd.com/read/27726294/role-of-comorbidity-on-outcome-of-head-and-neck-cancer-a-population-based-study-in-thuringia-germany
#19
Irene Göllnitz, Johanna Inhestern, Thomas G Wendt, Jens Buentzel, Dirk Esser, Daniel Böger, Andreas H Mueller, Jörn-Uwe Piesold, Stefan Schultze-Mosgau, Ekkehard Eigendorff, Peter Schlattmann, Orlando Guntinas-Lichius
To examine the impact of comorbidity on overall survival (OS) in a population-based study of patients with head and neck cancer who were treated between 2009 and 2011. Data of 1094 patients with primary head and neck carcinomas without distant metastasis from the Thuringian cancer registries were evaluated concerning the influence of patient's characteristics and comorbidity on OS. Data on comorbidity prior to head and neck cancer diagnosis was adapted to the Charlson Comorbidity (CCI), age-adjusted CCI (ACCI), head and neck CCI (HNCCI), simplified comorbidity score (SCS), and to the Adult Comorbidity Evaluation-27 (ACE-27)...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27730326/radiotherapy-for-elderly-patients-and-cetuximab-a-monocentric-study
#20
Alexander T Falk, Christophe Hébert, Antoine Tran, Marie-Eve Chand, Axel Leysalle, Juliette Thariat, Olivier Dassonville, Gilles Poissonnet, Alexandre Bozec, Esma Saada, Fréderic Peyrade, Karen Benezery
Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012...
February 2017: European Archives of Oto-rhino-laryngology
label_collection
label_collection
1405
1
2
2016-10-15 18:15:38
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"